Here's an article from Matthew Herper's column in Forbes that discusses whether the first drug that costs more than $1 million annually is already on the market -- and we just don't realize it yet. Interesting to ponder for sure -- and perhaps horrifying.
I wonder if this is a reason that many people back the concept of biosimilars down the road. Seems clear [to me] that governments won't sustain this type of pricing for long.
Posted by Bruce Lehr May 1st 2012.